Vaccines for caseous lymphadenitis: up-to-date and forward-looking strategies.

Abstract

Caseous lymphadenitis (CLA) is an infectious chronic disease responsible for economic losses in sheep and goat breeding worldwide. CLA has no effective treatment, evidencing the vaccination schedule as the best control strategy. Although some commercial vaccines have been available, none of them provides total protection, which is sometimes insufficient and does not reach the same efficiency when compared in sheep and goats. They also have questionable safety levels and side effects. In light of this, several experimental vaccines are in development in order to improve safety, reproducibility, and protective immune response against the etiologic agent of CLA, Corynebacterium pseudotuberculosis. In this review, we discussed aspects as antigen, adjuvant, routes of administration, protection level, and animal models used in CLA vaccine development, as well the challenges and future perspectives. KEY POINTS: Caseous lymphadenitis (CLA) does not have an appropriate commercial vaccine. Different experimental vaccines are in development aiming to protect against Corynebacterium pseudotuberculosis. An ideal vaccine for CLA is necessary for the disease control.

• Authors: Rodrigo Barros de Pinho, Mara Thais de Oliveira Silva, Francisco Silvestre Brilhante Bezerra, Sibele Borsuk
• Journal: Applied microbiology and biotechnology (Appl Microbiol Biotechnol) Vol. 105 Issue 6 Pg. 2287-2296 (Mar 2021) ISSN: 1432-0614 [Electronic] Germany
• PMID: 33651132 (Publication Type: Journal Article, Review)

Chemical References

• Bacterial Vaccines

Topics

• Animals
• Bacterial Vaccines
• Corynebacterium Infections (prevention & control, veterinary)
• Corynebacterium pseudotuberculosis
• Goats
• Lymphadenitis (prevention & control, veterinary)
• Reproducibility of Results
• Sheep
• Sheep Diseases